PDCD1 and glioblastoma: These programs were also applied in their reanalysis of scRNA‐seq data from Mei et al. [36], where recurrent GBM patients received neoadjuvant PD‐1 blockade and were classified as responders (n = 7) or non‐responders (n = 5) based on MRI follow‐up, although this classification does not directly establish causality.